New Heart Drug Sotagliflozin Shows Preclinical Promise
The drug shows potential for heart disease treatment in early research ahead of phase 3 human clinical trial results.
Updated on Oct. 21, 2026 in Heart Disease
Live Poll
Is current pharmaceutical research into cardiovascular treatments sufficient to address unmet patient needs?
Lexicon Pharmaceuticals recently published two preclinical studies exploring how the dual SGLT2 and SGLT1 inhibitor sotagliflozin affects cardiovascular health. These findings offer early insights into potential treatments for hypertrophic cardiomyopathy and thrombosis, as researchers look toward upcoming clinical trial data.
Why it matters
Understanding how dual inhibition affects cardiac pathways is essential for researchers developing new therapies for heart disease. By identifying specific mechanisms of action, these studies provide the biological foundation for ongoing human testing in larger patient populations.
The findings consist of two preclinical studies, one utilizing a mouse model and another examining human blood and animal models, to observe drug effects. Whether these laboratory results translate into clinical success remains to be determined in future human trials.
The players
Lexicon Pharmaceuticals
A biopharmaceutical company based in The Woodlands, Texas, focused on developing treatments for cardiovascular and metabolic conditions.
The details
Sotagliflozin functions as an oral dual inhibitor of SGLT2 and SGLT1 proteins. In myocardial tissues, the drug appears to reduce oxidative stress while upregulating mitochondrial gene sets, which may help improve cardiac structure. Additionally, the drug prevents platelet activation and thrombus formation without interfering with the body's normal hemostasis processes.
Timeline
October 21, 2026: Lexicon Pharmaceuticals released the findings of two new preclinical studies.
Q1 2027: The company expects to receive topline results from the Phase 3 SONATA-HCM clinical trial.
Health Landscape
This research contributes to the expanding field of SGLT inhibition as a strategy for treating heart disease beyond traditional metabolic applications. These preclinical insights provide the scientific framework for the ongoing Phase 3 SONATA-HCM clinical trial.
These results are strictly preclinical and do not currently change treatment guidelines for patients with heart disease. Anyone interested in emerging therapies for hypertrophic cardiomyopathy should discuss ongoing research and clinical trial eligibility with their cardiologist.
The takeaway
The dual inhibition of SGLT1 and SGLT2 may offer new pathways for improving cardiac structure and managing blood clot risks. Patients monitoring cardiovascular health trends should keep an eye on clinical trial announcements to see how these early laboratory findings translate into human medicine.
What happens next
Lexicon Pharmaceuticals expects to release topline results from its Phase 3 SONATA-HCM clinical trial in the first quarter of 2027.
Further reading
For more on the current standard of care and experimental treatments, explore our section on Heart Disease.
More information
Find more details on the company's research pipeline at the Lexicon Pharmaceuticals corporate information portal.
Live Poll
Is current pharmaceutical research into cardiovascular treatments sufficient to address unmet patient needs?
